血清CEA、AFP、CA19-9和SA联检对HCC的诊断价值

Diagnostic Value of Combined Measurement of Serum CEA,AFP,CA19-9 and SA Levels in Patients with Primary Hepatic Cancer

目的:探讨了肿瘤标志物癌胚抗原(CEA)、甲胎蛋白(AFP)、糖类抗原CA19-9(CA19-9)和唾液酸(SA)联检对原发性肝癌(HCC)的临床评价。方法:应用放免法和生化法对36例HCC患者进行了血清CEA、AFP、CA19-9和SA检测,并与35名正常健康人作比较。结果:以单一指标阳性作为诊断标准,CEA、AFP、CA19-9和SA对HCC的敏感性分别为33.3%、69.4%、58.3%、61.1%,特异性分别为60.4%、81.3%、68.8%、64.6%。联检结果二项或二项以上阳性作为标准。本文患者诊断灵敏度为94.4%、特异性为95.8%。结论:联检血清CEA、AFP、CA19-9和SA对HCC的辅助诊断有较高的临床实用价值。

Objective To study the diagnostic value of combined measurement of serum CEA,AFP,CA19-9 and SA levels for primary hepatic cancer.Methods Serum CEA,AFP,CA19-9（with RIA）SA（with biochemistry）levels were measured in 36 patients with primary hepatic cancer and 35 controls.Results As a single tumor marker for diagnosis,the sensitivity of CEA,AFP,CA19-9,SA was 33.3%,69.4%,58.5% and 61.1% respectively,the specificity was 60.4%,81.3% 68.8%,64.4% respectively.With combined detection of the four markers and assuming two or more markers positive as positive,the sensitivity would be 94.4% and specificity would be 95.8%.Conclusion Combined measurement of serum CEA,AFP,CA19-9 and SA levels is of clinical usefulness for diagnosis of primary hepatic cancer.